TrialRheumatology (Oxford, England)2026

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.